NanoViricides Inc. has announced promising research results for its broad-spectrum antiviral drug candidate, NV-387. The company reports that NV-387 has demonstrated substantial superiority over existing treatments like Tamiflu and Xofluza in animal models of Influenza A/H3N2 lethal lung infection. NV-387 is also active against coronaviruses, RSV, and other viruses that use heparan sulfate features to infect human cells. The company emphasizes that NV-387’s unique mechanism makes it difficult for viruses to develop resistance, addressing a major limitation of current antiviral therapies. These findings highlight NV-387’s potential as a future dominant player in the treatment of acute and severe acute respiratory infections. The timeline for the presentation of these results has not been specified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1126644) on January 13, 2026, and is solely responsible for the information contained therein.